בליאומיצין PFI

Country: Israel

Language: Hebrew

Source: Ministry of Health

Active ingredient:

BLEOMYCIN SULFATE

Available from:

MEGAPHARM LTD

ATC code:

L01DC01

Pharmaceutical form:

אבקה להכנת תמיסה לזריקה

Composition:

BLEOMYCIN SULFATE 15000 IU/VIAL

Administration route:

לתוך קרום הריאה, תוך-עורקי, תוך-ורידי, תת-עורי, תוך-שרירי, לתוך בקע

Prescription type:

מרשם נדרש

Manufactured by:

BAXTER ONCOLOGY GmbH, GERMANY

Therapeutic group:

BLEOMYCIN

Therapeutic area:

BLEOMYCIN

Therapeutic indications:

Bleomycin is useful in the management of the following neoplasms: Squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesaphagus, cervix, vagina, penis and skin. Well differentiated tumors usually respond better than anaplastic ones.Hodgkin's disease and other malignant lymphomas, including mycosis fungoides. Testicular carcinoma (seminoma and no seminoma) .Malignant effusions of serous cavities (intrapleural and intraperitoneal).Secondary indications in which bleomycin has been shown to be of some value include metastatic malignant melanoma, carcinoma of the thyroid lung and bladder. Local treatment of refractory warts. Bleomycin can be used as a single agent, but is generally used in combination with other cytotoxics and/or with radiation therapy.

Authorization date:

2020-09-30